A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial

Summary

Third Opinion Trial Synopsis:
This study wants to find out how well teclistamab works at the recommended Phase 2 dose.

*Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?

Contacts: